Keywords: Janssen, Johnson & Johnson, Canagliflozin, Type 2 diabetes, Mitsubishi Tanabe

Janssen files NDA with FDA for canagliflozin in type 2 diabetes

Article | 01 June 2012

Print This

Janssen Research & Development, a subsidiary of health care giant Johnson & Johnson (NYSE: JNJ) has submitted a New Drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in